Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 315 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Transplant Failure Clear all
Not yet recruiting Not applicable Interventional

Development and Test of a Communication Skills Training for Transplant Providers - Aims 2 & 3

NCT06182475
View directory record Official record
Conditions
Kidney Disease, Chronic, End Stage Renal Disease, Kidney Replacement
Interventions
EPPComm Provider Training
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Livingston, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 1:08 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Pentoxyfylline, Placebo, AMO Therapy
Drug
Lead sponsor
Patrick Northup, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib for Desensitization

NCT03213158
View directory record Official record
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
Ixazomib Oral Capsule
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 7, 2026, 1:08 AM EDT
Not listed Phase 1Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

NCT00498160
View directory record Official record
Conditions
Renal Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 7, 2026, 1:08 AM EDT
Recruiting Not applicable Interventional

CAPABLE Transplant

NCT06326905
View directory record Official record
Conditions
Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions
CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementation of the Live Donor Champion Program

NCT03435510
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Live Donor Champion Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 7, 2026, 1:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

NCT06878560
View directory record Official record
Conditions
ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Interventions
10 GE Xenokidney
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

NCT02544113
View directory record Official record
Conditions
Liver Failure
Interventions
Thymoglobulin, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Weston, Florida • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 7, 2026, 1:08 AM EDT
Not yet recruiting Phase 2 Interventional

(TNX-1500) in Kidney Transplant Recipients

NCT07204080
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
Interventions
TNX-1500, Kidney Transplant
Drug · Procedure
Lead sponsor
Ayman Al Jurdi, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Not applicable Interventional

N-acetylcysteine in Liver Transplantation

NCT00736541
View directory record Official record
Conditions
End Stage Liver Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
Ibtesam Hilmi
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

NCT01666951
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro tablets, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 7, 2026, 1:08 AM EDT
Active, not recruiting Not applicable Interventional

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04646226
View directory record Official record
Conditions
End-Stage Kidney Disease, Hemodialysis Complication
Interventions
AV graft, surgical intervention for creation of a fistula
Device · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 1:08 AM EDT
Terminated Phase 2 Interventional

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 7, 2026, 1:08 AM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 7, 2026, 1:08 AM EDT
Completed No phase listed Observational

Live Kidney Donor Study

NCT00608283
View directory record Official record
Conditions
Kidney Transplantation, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 7, 2026, 1:08 AM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 7, 2026, 1:08 AM EDT
Active, not recruiting Not applicable Interventional

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

NCT05613010
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient, Adherence, Treatment
Interventions
mHealth Messaging Intervention Group
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 1:08 AM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 7, 2026, 1:08 AM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 7, 2026, 1:08 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

NCT01878786
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
Drug
Lead sponsor
Matthew Cooper
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 7, 2026, 1:08 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 1:08 AM EDT
Completed Not applicable Interventional

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT05879302
View directory record Official record
Conditions
End Stage Renal Disease, End-Stage Kidney Disease, Kidney Transplantation, Esrd
Interventions
Kidney Offer Shared Decision Making
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 7, 2026, 1:08 AM EDT